Overview

Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI

Status:
Withdrawn
Trial end date:
2021-05-30
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of Ticagrelor versus Clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary drug-eluting stents.
Phase:
Phase 3
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
Treatments:
Clopidogrel
Ticagrelor
Ticlopidine